Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2012

View Archived Issues

Allergan presents new S1P1 receptor ligands

Randomized trial shows benefit of armodafinil in patients with traumatic brain injury

Phase I/Ib trial evaluates AUY-922 alone and with bortezomib

Encouraging phase II results presented on PD-0332991

New LDL-PLA2 inhibitors developed by GlaxoSmithKline

Italian researchers disclose novel EP4 receptor antagonists

Roche divulges novel Mdm2/p53 interaction inhibitors

Chinese group reports new antivirals

U.S. university patents new polypeptides

Epizyme synthesizes novel DOT1-like protein inhibitors

Amitiza approved in Japan

Debio-0932 shows promising activity in patients with advanced solid tumors

Sirnaomics plans siRNA-based therapeutic study in China

Ultragenyx begins dosing in new UX-001 study

Pfizer grants ChemRar rights to DPP IV inhibitor

Prosonix and Imperial College London to collaborate on engineered combination respiratory medicines

FDA accepts Adasuve NDA resubmission

Optimer obtains approval in Canada for CDI treatment

Health Canada approves Jakavi for treatment of patients with myelofibrosis

New models of kidney cancer developed in U.S.

MK-6096 effective in multinational trial

Companies file application in Japan for oral imaging agent for malignant glioma

FDA approves first test for quantifying CMV DNA in human plasma

Amgen completes acquisition

New public-private partnership aims to develop pediatric formulation of schistosomiasis treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...